Dr. Reddys Laboratories is currently trading at Rs. 2792.90, up by 16.45 points or 0.59% from its previous closing of Rs. 2776.45 on the BSE.
The scrip opened at Rs. 2782.90 and has touched a high and low of Rs. 2812.00 and Rs. 2782.00 respectively. So far 17194 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2875.00 on 04-Feb-2019 and a 52 week low of Rs. 1888.00 on 21-May-2018.
Last one week high and low of the scrip stood at Rs. 2812.00 and Rs. 2731.10 respectively. The current market cap of the company is Rs. 46398.83 crore.
The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 45.67% and 13.94% respectively.
Dr. Reddy's Laboratories has launched Tadalafil Tablets USP, a therapeutic equivalent generic version of Cialis (tadalafil) Tablets in the United States (US) market, approved by the US Food and Drug Administration (USFDA).
The Cialis brand and generic had US sales of approximately $1.7 billion MAT for the most recent twelve months ending in January 2019 according to IMS Health. The company’s Tadalafil Tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1817.60 |
Dr. Reddys Lab | 1351.25 |
Cipla | 1475.90 |
Lupin | 2168.30 |
Zydus Lifesciences | 964.40 |
View more.. |